PBLA - InvestorNewsBreaks - Panbela Therapeutics Inc. (NASDAQ: PBLA) Closes on Public Offering Totaling About $8.5M
Panbela Therapeutics (NASDAQ: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, has closed on its previously announced public offering. The offering consisted of 2,270,000 shares of its common stock or prefunded warrants in lieu thereof as well as two classes of warrants to purchase up to 4,540,000 shares of common stock (public warrants). The offerings were at a purchase price of $3.75 per share and associated public warrants and $3.749 per prefunded warrant and associated public warrants. According to the announcement, the prefunded warrants have an exercise price of $0.001 per share. The company reported that gross proceeds from the public offering totaled an estimated $8.5 million before deducting placement agent fees, commissions and offering expenses. The company anticipates using the funds for continued clinical development of its product candidates as well as working capital, business development and other general corporate purposes. Roth Capital Partners acted as sole placement agent of the offering.
To view the full press release, visit https://ibn.fm/WLALW
About Panbela Therapeutics Inc.
Panbela Therapeutics is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. Panbela’s lead assets are Ivospemin (SBP-101) and Flynpovi. For more information about the company, please visit www.Panbela.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.